-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Opaganib in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Opaganib in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Opaganib in Colorectal Cancer Drug Details: Opaganib (ABC-294640) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Opaganib in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Opaganib in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Opaganib in Pancreatic Cancer Drug Details: Opaganib (ABC-294640) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Opaganib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Opaganib in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Opaganib in Solid Tumor Drug Details: Opaganib (ABC-294640) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Esmethadone Hydrochloride in Renal Failure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Esmethadone Hydrochloride in Renal Failure report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Esmethadone Hydrochloride in Renal Failure Drug Details: REL-1017 (D-methadone) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRX-012 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRX-012 in Alzheimer's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PRX-012 in Alzheimer's Disease Drug Details: PRX-012 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Opaganib in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Opaganib in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Opaganib in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: Opaganib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CD33 NKE in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CD33 NKE in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CD33 NKE in Relapsed Acute Myeloid Leukemia Drug Details:...
-
Product Insights
NewEbolavirus Infections (Ebola Hemorrhagic Fever) – Drugs In Development, 2024
Empower your strategies with our Ebolavirus Infections (Ebola Hemorrhagic Fever) – Drugs In Development, 2024 report and make more profitable business decisions. Ebola is a rare but deadly viral infection that causes bleeding inside and outside the body. Signs and symptoms include fever, severe headache, joint and muscle aches, sore throat, nausea and vomiting, diarrhea, chest pain, and cough. Supportive therapy includes oxygen therapy, blood transfusions, intravenous fluids, and pain relievers. The Ebolavirus Infections (Ebola Hemorrhagic Fever) drugs in development market...
-
Product Insights
NewChemotherapy Induced Nausea and Vomiting – Drugs In Development, 2024
Empower your strategies with our Chemotherapy Induced Nausea and Vomiting – Drugs In Development, 2024 report and make more profitable business decisions. Chemotherapy-induced nausea and vomiting (CINV) is nausea and vomiting that results specifically from treatment with chemotherapy drugs. Other symptoms include a rapid heart rate, sweating, dizziness, and increased saliva. Risk factors include age, drug, dose, and the schedule and route of the drug's administration. The Chemotherapy Induced Nausea and Vomiting drugs in development market research report provide comprehensive information...
-
Product Insights
NewHelicobacter pylori Infections – Drugs In Development, 2024
Empower your strategies with our Helicobacter pylori Infections – Drugs In Development, 2024 report and make more profitable business decisions. Helicobacter pylori (H. pylori) infection occurs when the Helicobacter pylori (H. pylori) bacteria infect the stomach, typically during childhood. A leading cause of stomach ulcers, this infection is asymptomatic for many, with over half of the global population potentially affected. Recognition often arises when peptic ulcer symptoms manifest, prompting healthcare providers to test for H. pylori. Peptic ulcers, affecting the stomach...